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Abstract 
The prevalence and impact of cardiovascular diseases in the world are growing. There are 2 million deaths due to 
cardiovascular disease each year in the European Union; the main cause of death being the coronary heart disease responsible for 
16% of deaths in men and 15% in women. Prevalence of cardiovascular disease in Romania is estimated at 7 million people, of 
which 2.8 million have ischemic heart disease. In this epidemiological context, risk stratification is required for individualization of 
therapeutic strategies for each patient. The continuing evolution of the diagnosis and treatment techniques combines personalized 
medicine with the trend of therapeutic management leveling, based on guidelines and consensus, which are in constant update. The 
guidelines used in clinical practice have involved risk stratification and identification of patient groups in whom the risk-benefit ratio of 
using new diagnostic and therapeutic techniques has a positive value. Presence of several risk factors may indicate a more 
important total risk than the presence / significant increase from normal values of a single risk factor. Modern trends in risk 
stratification of patients with coronary heart disease are polarized between the use of simple data versus complex scores, traditional 
data versus new risk factors, generally valid scores versus personalized scores, depending on patient characteristics, type of 
coronary artery disease, with impact on the suggested therapy. All known information and techniques can be integrated in a complex 
system of risk assessment. 
The current trend in risk assessment is to identify coronary artery disease in early forms, before clinical manifestation, and 
to guide therapy, particularly in patients with intermediate risk, which can be classified in another class of risk based on new obtained 
information. 
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Abbreviations: ACS = acute coronary syndrome; AMI = acute myocardial infarction; BNP = brain natriuretic peptide; BP = 
blood pressure;  BPs = systolic blood pressure; CHD= coronary heart disease; CRP = C-reactive protein; CX= circumflex 
artery; EF= ejection fraction; LAD= left anterior descendending coronary artery; LV = feft ventricle; MI= myocardial 
infarction; NGAL= neutrophil gelatinase associated lipocalin; NT-proBNP = N-terminal pro B-type natriuretic peptide; RCA= 
right coronary artery; RV= right ventricle 
 
General Information 
 
There are many classifications of known 
cardiovascular risk factors: major (showing a significant 
correlation with the risk of cardiovascular disease), 
associated (show a less significant correlation with 
cardiovascular risk); modifiable (can be controlled through 
diet / treatment) or not modifiable (i.e.: age, sex).[1] 
Classic risk factors are known: the INTERHEART study, 
which included the population in 52 countries, has 
identified nine risk factors responsible for over 90% of the 
myocardial infarction risk: smoking, dyslipidemia, 
hypertension, diabetes, obesity, diet, physical activity, 
alcohol consumption, psychosocial factors. [2] 
A recent study [3] has proposed to demonstrate 
the prognostic impact of physical examination in patients 
with acute coronary syndrome. The result was that the 
integration of information obtained from physical 
examination in Killip classification is an important 
predictor of death from any cause in patients with acute 
coronary syndromes, of significant importance being age, 
Killip class, heart rate, systolic blood pressure and ST 
segment depression. 
An example is the HNR (Heinz Nixdorf Recall) 
Study, which demonstrated the benefit of identifying 
subclinical atherosclerosis by using coronary calcium 
score, assessed by noninvasive CT, consisting of a high 
percentage of reclassification in the intermediate risk 
patient group and a more precise estimate of risk. 
Patients with intermediate risk (based on traditional risk Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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factors according to Framingham score) were reclassified 
according to calcium score results: <100 in the low-risk 
class and > 400 in the high-risk class. [4] 
 
Risk Assessment Systems 
 
A risk assessment system with a clinical utility 
must meet several criteria. It must use appropriate 
statistical methods, it must be performant (with internal 
and external validity), and it must include appropriate risk 
factors: with important discriminatory power, with 
prevalence in the target-population, and must be easy to 
use. [5] 
Risk scores use proportional semiparametric 
(Cox) and parametric (Weibull) statistical risk models, 
complex methods such as cluster analysis and tree-
structured analysis, or neural networks. [5] Risk scores’ 
performance is determined by the discrimination power 
(statistical parameters: AUROC and C Harrell test), 
calibration and reclassification (net reclassification index 
NRI). 
Theoretical performance of a risk score is 
important, but in order to become a useful clinical tool 
must be accessible: simple, must contain available 
parameters and identify patients who might benefit from a 
specific treatment. [6] A comparative study on the 
prognostic value of risk scales in acute coronary 
syndromes demonstrated the superiority of GRACE and 
PURSUIT scores, which are complex, but are difficult to 
apply at the bedside, over the TIMI score, which is 
simpler, but more frequently used in clinical practice. [7] 
The first step recommended in determining the 
patient’s risk is the calculation of the global cardiovascular 
risk, based on simple information, with the assessment of 
“classical” risk factors: age, sex, heredity, obesity, 
sedentary lifestyle, smoking, hypertension, diabetes 
mellitus, dyslipidemia, alcohol, psychosocial factors (i.e. 
Framingham, SCORE) and a careful clinical examination. 
The latter has an important prognostic value and 
constitutes the basis of several risk scores with wide 
application, such as the Killip classification in myocardial 
infarction. [8] 
 
Table 1 Comparison of risk factors considered in the overall cardiovascular risk scores (according to [9]) 
  Framingham  SCORE  PROCAM (men)  Reynolds (men) 
Risk factors  Age, sex, total cholesterol, 
HDL, smoking,  BPs, 
antihypertensive medication 
Age, sex, total 
cholesterol – HDL 
ratio, smoking, BPs 
Age, LDL, HDL, smoking,   
diabetes, BPs, triglycerides, 
family history 
Age, total cholesterol, 
HDL, smoking,  BPs, 
CRP, family history of 
MI at age <60 years 
Electronic 
address 
http://hp2010.nhlbihi.net/atp
iii/calculator. 
 
http://www. 
heartscore.org 
http://www.chdtaskforce.co
m/coronary_risk_assessme
nt.html 
http://www.reynoldsrisk
score.org/ 
 
Following initial assessment, patients are 
classified into three risk categories: low, intermediate or 
high, to guide therapeutic management. Thus, a patient 
classified as having a high risk will be subject to invasive 
investigations, without using additional methods to 
quantify risk. Instead, for a patient with intermediate risk, 
therapeutic decision can be influenced by the use of 
unconventional markers and modern, complex 
techniques, if they are able to reclassify the patient in a 
different class of risk: low or high. [9] New risk factors for 
atherosclerosis are described as: markers of 
inflammation, metabolic risk factors, thrombogenic 
factors, markers of subclinical atherosclerosis. 
Risk assessment is a dynamic process. 
Coronary Heart Disease Risk Assessment  
European Society of Cardiology suggests an 
algorithm for the evaluation of patients with acute 
coronary syndrome probability. The pain presence raises 
suspicion of acute coronary syndrome. The ECG may 
show ST segment elevation, normal pattern or atypical 
abnormalities. Depending on the biochemical markers 
(troponin) risk stratification can be made and therapeutic 
management can be guided. Afterwards, risk assessment 
will be made for secondary prevention. 
Stable angina 
Diagnosis of stable angina is primarily clinical 
and the leading role is the patient’s history. The most 
widely used classification is the Canadian Cardiovascular 
Society (CCS) Classification, describing four classes of 
risk depending on clinical features and circumstances of 
occurrence. [10] 
 
Table 2 Canadian Cardiovascular Society Functional Classification of Stable Angina (according to [10]) 
Class  Canadian Cardiovascular Society Functional Classification 
I  Ordinary physical activity does not cause angina, such as walking and climbing stairs. 
Angina with strenuous or rapid or prolonged exertion at work or recreation. 
II  Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking uphill, 
walking or stair climbing after meals, or in cold, or in wind, or under emotional stress, or only during the few hours 
after awakening.Walking more than 2 blocks on the level and climbing more than one flight of ordinary stairs at a 
normal pace and in normal conditions. 
III  Marked limitation of ordinary physical activity. Walking one to two blocks on the level and climbing one flight of 
stairs in normal conditions and at normal pace. Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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IV  Inability to carry on any physical activity without discomfort - anginal syndrome may 
be present at rest. 
There are other classification systems: Duke 
Activity Specific Index or Seattle Angina Questionnaire, 
which can provide additional prognostic information [11], 
but in daily clinical practice they are less used. 
The European Society of Cardiology [12] 
proposed a classification into three categories of annual 
cardiovascular mortality risk: low risk (<1%), intermediate 
risk (1-2%), elevated (>2%).  Risk stratification requires 
integration of clinical parameters, stress test results, 
ventricular function and coronary angiography diagnosis. 
Individual prognosis of patients with stable angina is 
variable and the therapeutic management is different 
depending on the risk degree. Initial clinical evaluation 
(history, physical examination), rest electrocardiogram 
and laboratory tests can reveal unstable angina, in which 
case, the therapeutic management is specific. If the initial 
evaluation is suggestive of stable angina without signs of 
severity, the next step is the assessment of ischemia by 
using stress tests (stress ECG, echocardiography, 
scintigraphy), but, if there are characters of gravity: ECG 
changes, myocardial infarction, signs of heart failure, 
hypertension, diabetes mellitus, the cardiac performance 
is assessed by using the cardiac ultrasound or the MRI. 
Data integration allows patients classification in risk 
classes and modulation of therapeutic conduct: medical 
treatement with assessment of the therapeutic efficiency 
or coronary angiography, to determine the optimal 
revascularization formula. 
The most important prognostic and survival 
factors in stable angina are left ventricular function, 
distribution and severity of coronary stenosis. [13] 
Two forms of atypical angina are: Coronary X 
Syndrome and the vasospastic angina. Coronary X 
syndrome is defined by typical effort angina, positive 
stress tests and permeable epicardial coronary arteries 
[14] and was classified as a form of primary microvascular 
stable angina, with a good prognosis.[15] In vasospastic 
angina, the mortality risk is determined by the presence 
and severity of coronary artery stenosis [16]  and the 
vascular hyperreactivity. 
 
Acute coronary syndromes without ST segment 
elevation 
Patients with acute coronary syndromes are a 
heterogenous group, with different risk of death or major 
cardiac events, and the initial assessment has an 
important role in the election of investigation and 
therapeutic decision. 
The first classification in a group of risk in 
patients with unstable angina is made through history, 
depending on the character and frequency of anginal 
pain. Risk stratification in these patients can be performed 
by Braunwald classification of unstable angina in three 
risk classes.[17] (according to Table 3) 
 
Table 3 Braunwald Classification of Unstable Angina (according to [17]) 
Class  Severity 
I  New onset of severe angina or accelerated angina; no rest pain 
II  Angina at rest within past month but not within preceding 48 h (angina at rest, subacute) 
III  Angina at rest within 48 h (angina at rest, acute) 
                      Clinical circumstances 
A  Develops in Presence of Extracardiac Condition That Intensifies Myocardial Ischemia (Secondary UA) 
B  Develops in absence of extracardiac conditions (Primary UA) 
C  Develops within 2 weeks of AMI (Postinfarction UA) 
 
Clinical evaluation, ECG and biological makers allow the initial assignment of patients in one of the risk groups: 
high, intermediate or low. [18] (according to Table 4) 
 
Table 4 Risk Stratification Based on Noninvasive Testing (according to [18]) 
Risk   Parameters 
1. Severe resting left ventricular dysfunction (LV EF < 35 %) 
2. High-risk treadmill score (score ≤ -11) 
3. Severe exercise left ventricular dysfunction (exercise LV EF < 35 %) 
4. Stress-induced large perfusion defect (particularly if anterior) 
5. Stress-induced multiple perfusion defects of moderate size 
6. Large, fixed perfusion defect with LV dilation or increased lung uptake (thallium-201) 
8. Echocardiographic wall motion abnormality (involving > two segments) developing at low dose of 
dobutamine (≤10 mg/kg/min) or at a low heart rate (<120 bpm) 
High Risk 
>3% annual 
mortality rate 
9. Stress echocardiographic evidence of extensive ischemia 
1. Mild/moderate resting left ventricular dysfunction (LV EF = 35–49%) 
2. Intermediate-risk treadmill score (-11 < score < 5) 
3. Stress-induced moderate perfusion defect without LV dilation or increased lung intake (thallium-201) 
Intermediate Risk  
1–3% annual 
mortality rate 
4. Limited stress echocardiographic ischemia with a wall motion abnormality only at higher doses of 
dobutamine involving ≤ two segments 
Low Risk   1. Low-risk treadmill score (score ≥ 5) Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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2. Normal or small myocardial perfusion defect at rest or with stress   mortality rate 
3. Normal stress echocardiographic wall motion or no change of limited resting wall motion abnormalities 
during stress  
TIMI Score uses data on age, frequency of 
anginal episodes, risk factors and history of coronary 
artery stenosis, drug therapy (aspirin) and values of 
cardiac biomarkers. It is easy to calculate, each of the 
seven items of the questionnaire receiving 0 or 1 point, 
with a maximum score 7, and can be applied even in non-
specialized areas. 
 
Table 5 TIMI risk score (according to [19]) 
Characteristics  Age > 65 years 
  At least 3 risk factors for CHD1 
  Significant coronary stenosis (eg, prior coronary stenosis ≥ 50%) 
  ST deviation 
  Severe anginal symptoms (eg,  > 2 anginal events in last 24 h) 
  Use of aspirin in last 7 days 
  Elevated serum cardiac markers2 
Score  Rates of all-cause mortality, myocardial infarction, and severe recurrent ischemia prompting 
urgent revascularization through 14 days 
0/1 
2 
3 
4 
5 
6/7 
             4,7% 
             8,3% 
           13,2% 
           19,9% 
           26,2% 
           40,9% 
1Risk factors include: family history of CHD, hypertension, hypercholesterolemia, diabetes, or being a current smoker;  
2Creatine kinase MB fraction and/or cardiac-specific troponin level. 
 
It has a superior prognostic value compared to 
solely using ECG and troponin [20], even if it has a less 
accurate predictive value of cardiovascular events.[18] 
TIMI score has been validated in unselected cases of 
suspected acute coronary syndrome, myocardial 
infarction with or without ST segment elevation, is used in 
analyzing tratement efficacy and identifying patients with 
different response to treatment. 
GRACE risk score is based on the analysis of an 
international registry that included an unselected group of 
patients with acute coronary syndromes and evaluates 
clinical data, ECG and biological information: such as 
age, heart rate, systolic blood pressure, Killip class, the 
ECG changes, cardiac biomarkers, as well as two 
variables not previously identified: baseline creatinine 
level and cardiac arrest. This score has a significant 
discriminative power in assessing the risk of intra-hospital 
mortality, hospital discharge and at 6 months; patients are 
classified into three risk groups: low, intermediate and 
high. [21,22] 
 
Table 6 In-hospital mortality and 6 months mortality according to GRACE risk score (according to [22]) 
Risk grade  Score  In-hospital mortality (%) 
Low risk  ≤ 108  < 1 
Intermediate risk  109 - 140  1 – 3 
High risk  >  140  > 3 
Risk grade  Score  Mortality at 6 months (%) 
Low risk  ≤ 88  < 3 
Intermediate risk  89 - 118  3 - 8 
High risk  >  118  > 8 
 
It is difficult for bedside use, but there are 
applications that facilitate automatic online calculating. 
Howerver, this is the optimum risk stratification score for 
daily practice, at admission and discharge. [18,23] 
FRISC score is the only score that has a high 
capacity to identify patients who have a long-term benefit 
from an early invasive treatment strategy. [18,24] 
PURSUIT score allows risk stratification in 
patients with unstable angina and myocardial infarction 
without ST segment elevation. [25] 
Each investigation contributes to determining the 
patient’s degree of risk. Thus, biological analysis provides 
important information by evaluating traditional biomarkers, 
as well as novel markers. For risk stratification, the Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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following markers can be used: of myocardial necrosis, 
inflammation, hemodynamic stress and neurohormonal 
activation, renal impairment, vascular injury and 
accelerated atherosclerosis (Table 7). 
Table 7 Types of biomarkers used in risk stratification and choice of appropriate therapy in acute coronary syndromes (according to [18]) 
Markers  Example 
Necrosis markers  Troponin 
Inflammation markers   CRP, myeloperoxidase, pregnancy-associated plasma protein A, soluble ligand CD-40, 
interleukin 6 
Hemodynamic stress and 
neurohormonal activation 
BNP, NT-proBNP 
Renal impairment  NT-proBNP, creatinine clearance, cystatin C, NGAL 
Bioumoral particular context, vascular 
injury 
Fibrinogen, platelet agregability 
Accelerated atherosclerosis  Hemoglobin A1C 
 
The most important marker for the diagnosis and 
early risk stratification is troponin, which allows the 
differentiation between unstable angina and myocardial 
infarction, without ST segment elevation; with an 
important prognostic value (high levels are correlated with 
a poor prognosis). [26] Dynamic evaluation of creatine-
kinase and creatine-kinase MB has a high prognostic 
value, so brain natriuretic peptide (BNP) and C-reactive 
protein (CRP) are recommended for additional grading. 
Multiple studies have proven that BNP is an important 
prognostic biomarker in patients with acute coronary 
syndromes. C-reactive protein allows risk stratification, 
especially in patients grouped on the basis of traditional 
risk factors in the intermediate risk class [27], as an 
independent maker or in combination with troponin T 
value [28], but there are studies (RISCA), showing that it 
does not provide additional long-term prognostic 
information. [29] 
    It should be noted that the use of biological 
markers should be performed and interpreted in a clinical 
context. For example, homocysteine evaluation is not 
recommended in all patients to identify risk, but has 
additional value for patients with intermediate risk. [28] 
We are now trying to identify the prognostic 
value and the limits of individual markers and association 
of different investigations to allow data integration into risk 
scores (similar to clinical scores), “multi-marker strategy” 
to achieve a better risk grading [18], mentioning that there 
are also limits to be known (the synergistic effect of 
markers). 
The modern concept of risk stratification is a 
“dynamic risk model”, [29] representing the parallel 
evolution of risk markers with the disease, their dynamic 
interpretation. This is why the reassessment of risk after 
the first day and at discharge is of great importance. 
 
Acute coronary syndromes with ST segment 
elevation 
Risk stratification in acute coronary syndromes with ST 
segment elevation - pre-hospital 
Myocardial infarction with ST segment elevation 
has a high mortality rate, especially in the first 2 hours 
after onset, before patients reach hospital, and the 
reasons are: the incidence of malignant arrhythmias, 
ignoring or misinterpreting different types of 
haemodynamic instability, lack of early coronary 
reperfusion procedures [30], so that the quick, correct 
diagnosis and risk assessment of these patients pre-
hospital is essential. 
Risk assessment in pre-hospital occurs mainly 
based on clinical, electrocardiographic and paraclinical 
data. The following clinical characteristics suggest an 
increased vital risk: age over 70 years, signs of tissue 
hypoperfusion, systolic blood pressure <120 mmHg, 
tachycardia > 110 bpm or bradycardia <60 bpm, 
psychomotor agitation, pulmonary rales or protodiastolic 
gallop. [30] 
 
Table 8: Clinical criteria for assessing risk in patients with acute myocardial infarction - pre-hospital (according to [30]) 
Parameter  Low risk  High risk 
 Age (years)  < 70  > 70 
AV (bpm)  >60 , < 110  <60, >110 
TAs (mmHg)  > 120  < 120 
Pulmonary rales  No  Yes 
3rd Sound  No  Yes 
Signs of shock  No  Yes 
 
The parameters mentioned above allow the risk 
grading in Killip class, a simple classification and widely 
used in clinical practice. It also allows the identification of 
hemodynamic profile: normodinamic, hiperdinamic 
syndrome, hypotension, bradycardia, hypovolemia, 
cardiac pump failure, RV myocardial infarction, 
cardiogenic shock. [30] 
 Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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Table 9 Hemodynamic profiles in patients with acute myocardial infarction (according to [30]) 
Hemodynamic 
profile 
Dyspn
oea 
SBP 
mmHg 
AV 
bpm 
Tegume
nts 
Cianosi
s 
Jugular 
veins 
Rales  Diuresis 
Normodynamic   -  N  N  N  -  N  -  N 
Hyperdynamic  -  >140  >120  N  -  N  -  N 
Hypotension - 
bradycardia 
-  <95  <60  N  -  N  -  N 
Hypovolaemia  -  <95  >100  N  -  N  -  N/oliguria 
Pump failure  +/++/++
+ 
N/<95  N/>100  N/cold  -  N/turg  +/++/+++  N/oliguria 
RV infarction  -/+  N/<95  >100  cold  ++  N/turg  -/+  N/oliguria 
Cardiogenic shock  +++  <95  >100  cold  +++  N/turg  +++  oliguria 
N= normal 
 
The ECG provides data for risk stratification in 
acute coronary syndromes with ST segment elevation 
electrocardiogram, and can often be done pre-hospital, 
allowing Topol grading. 
Paraclinical risk criteria are the arterial oxygen 
saturation reduction < 90% [2], a parameter easily 
obtained by the use of pulse oximetry, hyperglycemia > 
120 mg / dl (correlated to 3 fold increased risk of 
death)[31], increased levels of troponin in the first 6 hours 
after symptoms onset. [32] 
An important aspect is the early initiation of 
therapy in patients with myocardial infarction with ST 
segment elevation in pre-hospital with antiplatelets, 
anticoagulants and even fibrinolytic medication. In this 
case risk assessment is essential to identify patients with 
bleeding and increased bleeding risk, represented by: 
bleeding disorders, history of ulcer disease or 
gastrointestinal bleeding, anemia without a known cause, 
severe hypertension, history of ischemic or hemorrhagic 
stroke (including transient), signs of senile dementia, 
recent head trauma, recent surgery (last three weeks), 
body weight below 65 kg. [33,34] 
 
Risk stratification in acute coronary syndromes with ST 
segment elevation - in hospital 
Initial assessment at hospital admission of 
patients with acute coronary syndromes with ST segment 
elevation should use two risk scales: clinical (Killip) and 
ECG (Topol). Killip Classification (1967) is still useful in 
clinical practice even if the impact on mortality has 
decreased due to enlargement of the therapeutic arsenal. 
[35] 
 
Table 10 Killip classification of acute myocardial infarction (modified after [34,35]) 
Class  Clinic  “Historical” mortality (%)  Mortality at 30 days (GUSTO-
1) (%) 
I  No rales, no 3rd heart sound  8,4  5,1 
II  Pulmonary congestion with rales < 50% of the 
lung fields or 3rd heart sound 
30,5  13,6 
III  Pulmonary oedema with rales > 50% of the lung 
fields  
44  32,2 
IV  Cardiogenic shock  82,1  57,8 
 
The ECG allows rapid risk evaluation of patients with myocardial infarction with ST segment elevation, including 
them into one of the five Topol classes, the most reserved prognosis being for class Topol I. [36] 
 
Table 11 Topol Classification of MI based on ECG at admission correlated with angiographic data (according to [36]) 
  Occlusion location  ECG at admission  Mortality at 
30 days 
Mortality at 1 
year 
1. LAD -proximal  Before the first septal 
perforating artery 
↑ST in DI, aVL, V1-V6 and fascicular 
block or bundle branch block 
19,6%  25,6% 
2. LAD - medium  After the first septal 
erforating artery, 
before the great 
diagonal artery 
↑ST in DI, aVL, V1-V6  9,2%  12,4% 
3. LAD - distal or 
Diagonal artery 
After the great 
diagonal artery or first 
diagonal leasion 
↑ST in V1-V4 or ↑ST in DI, aVL, V5-V6  6,8%  10,2% 
4. Inferior moderate 
MI (RV, posterior, 
lateral) 
Proximal RCA or CX  ↑ST in DII, DIII, aVF and any or all of the 
following: 
a) V1, V3R, V4R 
b) V5-V6 
c) R>S in V1-V2 
6,4%  8,4% 
5. Inferior small MI   Distal RCA or CX or 
CX branches 
↑ST in DII, DIII, aVF  4,5%  6,7% Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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Location of ECG changes, ST segment elevation 
amplitude and QRS duration are electrocardiographic 
features with prognostic value, correlated with the risk of 
adverse events.[37] ST segment elevation in aVR 
derivation has a controversial prognostic value, but a 
value >1.5 mm associated with anterior myocardial 
infarction and a value >1 mm associated with inferior 
myocardial infarction, in patients without intraventricular 
conduction disturbances, is associated with increased 
mortality at 30 days.[38] Markers with predictive value of 
myocardial revascularization success are described: 
terminal QRS distorsion (grade 3 ischemia) on the initial 
ECG is an independent predictor marker for coronary 
reperfusion absence after primary angioplasty.[39] 
Mortality risk in patients with AMI can be 
assessed according to clinical and hemodynamic 
parameter values: cardiac index and pulmonary capillary 
pressure (obtained by right cardiac catheterization), 
according to Forrester classification, rarely used today. 
Normal hemodynamic profile includes patients with 
normal cardiac output (> 2.2 l/m/m2) and pulmonary 
capillary wedge pressure < 18 mmHg, increased pressure 
in the pulmonary capillary under a normal cardiac output 
corresponds to patients with acute pulmonary edema, 
patients with hypovolemic status presents low cardiac 
output and pulmonary capillary pressure at low, while 
patients in cardiogenic shock present a low cardiac output 
in the presence of increased pressure in the pulmonary 
capillary.[40] 
Summing up the information provided by clinical 
and ECG data, the most important independent 
prognostic markers are older age, higher Killip class, and 
presence of tachycardia, hypotension and anterior 
location of the myocardial infarction.[41] Independent 
predictive value also have: history of a myocardial 
infarction, time to treatment, height, weight, diabetes and 
smoking.[42] Initial echocardiographic evaluation brings 
information on the location and extent of the myocardial 
infarction; LV systolic function was correlated with long-
term prognosis in these patients.[43] 
Risk assessment in acute coronary sindrom with 
ST segment elevation is a continuous process, so that 
each diagnostic step brings additional information and 
allows a dynamic stratification of the patients’ risk. 
Coronary angiography allows assessing the coronary 
anatomy, coronary lesions, the best therapeutic option, 
the opportunity and myocardial revascularization modality. 
 
Table 12 Indications for myocardial revascularization modality of choice (surgical versus interventional) (according to [44]) 
Coronary anatomy  CABG  PCI 
1VD or 2VD – non-proximal LAD  IIbC  IC 
1VD or 2VD – proximal LAD  IA  IIa B 
3VD simple lesions, full functional revascularization achievable with PCI, SYNTAX 
score ≤22 
IA  IIa B 
3VD complex lesions, incomplete revascularization achievable with PCI, SYNTAX 
score > 22 
IA  III A 
Left main (isolated or 1VD, ostium/shaft)  IA  IIa B 
Left main (isolated or 1VD, distal bifurcation)  IA  IIb B 
Left main + 2VD or 3VD, SYNTAX score ≤ 32  IA  IIb B 
Left main + 2VD or 3VD, SYNTAX score ≥33  IA  III B 
 
Currently, there are several risk stratification 
scores based on angiographic results (Table 13 and 14), 
but information on the comparative value of such scales 
of risk is limited, each using populations with different 
characteristics, the results being reported at different, not-
superimposable distances of time.[44] 
In case of interventional revascularization, it is 
important to grade the coronary flow (TIMI) and the 
myocardial blush (MBG- a semiquantitatively parameter 
dependent on the tissular phase of the myocardial 
perfusion), which are important prognostic factors. 
 
Table 13 Grading of coronary flow (according to [45]) 
Grade  Definition  
0 : no perfusion  - no antegrade flow beyond the point of occlusion 
1 : penetration with 
minimal perfusion 
- the contrast material passes beyond the area of obstruction, but "hangs up" and fails to opacify the 
entire coronary bed distal to the obstruction for duration of the cine run 
2 : partial perfusion  -the contrast material passes across the obstruction and opacifies the coronary bed distal to the 
obstruction; the rate of entry of contrast material into the vessel distal to the obstruction or its rate of 
clearance from the distal bed (or both) are perceptibly slower than its entry into or clearance from 
comparable areas not perfused by the previously occluded vessel, e.g., the opposite coronary artery or 
the coronary bed proximal to the obstruction. 
3 : complete 
perfusion 
- antegrade flow into the bed distal to the obstruction occurs as promptly as antegrade flow into the bed 
proximal to the obstruction, and clearance of contrast material from the involved bed is as rapid as 
clearance from an uninvolved bed in the same vessel or the opposite artery Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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Table 14 Grading of myocardial blush (according to [46]) 
MBG 0  no myocardial blush or contrast density; myocardial blush persisted ("staining"): leakage of the contrast 
medium into the extravascular space 
MBG 1  minimal myocardial blush or contrast density 
MBG 2  moderate myocardial blush or contrast density but less than that obtained during angiography of a 
contralateral or ipsilateral non–infarct-related coronary artery 
MBG 3  normal myocardial blush or contrast density, comparable with that obtained during angiography of a 
contralateral or ipsilateral non–infarct-related coronary artery 
 
After the primary angioplasty in acute myocardial 
infarction, the no-reflow phenomenon can be seen in 10 
to 40% of cases [41], characterized by the presence of 
coronary TIMI flow <3 or TIMI 3 but 0-1 myocardial blush, 
negative prognostic marker, correlated with a prolonged 
duration of myocardial ischemia, severe arrhythmias, 
hemodynamic deterioration, increased risk of mechanical 
complications. 
After reperfusion therapy, it is necessary to 
identify patients at high risk for reinfarction or death. In 
this respect it is important to assess infarct size and LV 
function at rest in the first 24-48 hours (if not performed 
previously to angioplasty). It is necessary to assess 
myocardial viability: using myocardial perfusion 
scintigraphy (with thallium-201 or technetium-99m), stress 
echocardiography (usually dobutamine), MRI or PET, as 
well as evaluating the risk of arrhythmia and to initiate 
sudden death prevention. Patients without symptomatic 
arrhythmias and with EF > 60% are at low risk, so you do 
not need further investigation. High risk patients have EF 
< 40%, heart failure symptoms, non-sustained ventricular 
tachycardia, sustained monomorphic ventricular 
tachycardia induced at electrophysiological study. Other 
risk factors are: T wave alternation, heart rate variability, 
QT dispersion, baro-reflex sensitivity, signal-gated ECG. 
[41] 
Risk evaluation in patients with acute coronary 
syndromes is dynamic, with reassessment after each 
diagnostic or therapeutic step, with impact on the 
investigation plan, therapeutic management, with 
identification of immediate and long-term prognosis. 
Modern risk stratification in coronary artery 
disease involves a complex approach (incorporating data 
and taking into account traditional risk factors 
unconventional) and personalized. 
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